Shareholders' Equity (Details) $ / shares in Units, $ in Thousands						1 Months Ended				3 Months Ended	12 Months Ended				15 Months Ended
	Oct. 02, 2024 USD ($) $ / shares shares	Apr. 22, 2024 USD ($) $ / shares shares	Jan. 07, 2024 USD ($) shares	Oct. 05, 2023 USD ($) $ / shares shares	Oct. 03, 2022 shares	Dec. 31, 2024 USD ($) shares	May 31, 2024 USD ($) shares	Dec. 31, 2023 USD ($) shares	Oct. 31, 2022 $ / shares shares	Mar. 31, 2024 USD ($) shares	Dec. 31, 2024 USD ($) shares	Dec. 31, 2024 USD ($) shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2024 USD ($) shares	Aug. 31, 2024 USD ($)	May 01, 2024 USD ($) $ / shares shares	Oct. 31, 2023 USD ($)
Sale of Stock [Line Items]
Obligation to issue common shares as payment under license and other agreements | $												$ 8,554
Common stock issued (shares)								721,136
Issuance of common shares, net of offering costs | $								$ 21,814				$ 664,015	$ 242,425	$ 282,804
Shares converted due to spinoff (in shares)					0.5
Shares issued in spinoff (in shares)					35,840,459
Pyramid
Sale of Stock [Line Items]
Upfront payment of common shares, shares (in shares)			255,794,000
Upfront payment of common shares, value | $			$ 10,894
Upfront payment of common shares, shares issued (in shares)											253,838,000
R&D expense | $										$ 5,689
Common shares issuable (in shares)										98,129
Common shares issued (in shares)												97,387
Purchase Agreement, Knopp Amendment
Sale of Stock [Line Items]
Number of securities called by warrants (shares)																	294,195
Exercise price of warrants (in dollars per share) | $ / shares																	$ 67.98
Warrants, fair value disclosure | $																	$ 3,340
Purchase Agreement, Knopp Amendment
Sale of Stock [Line Items]
Common stock issued (shares)							1,872,874
Issuance of common shares, net of offering costs | $							$ 65,981
FGFR3 Agreement, GeneQuantum Healthcare Co. Ltd. and Aimed Bio, Inc.
Sale of Stock [Line Items]
Obligation to issue common shares as payment under license and other agreements (in shares)						222,119
Obligation to issue common shares as payment under license and other agreements | $						$ 8,554
Common Shares
Sale of Stock [Line Items]
Common stock issued (shares)												16,752,439	11,761,363	28,750,000
Issuance of common shares, net of offering costs | $												$ 664,015	$ 242,425	$ 282,804
Number of shares sold in transaction (in shares)	6,052,631	6,451,220
Issuance price per share (in dollars per share) | $ / shares	$ 47.50	$ 41.00
Proceeds from sale of stock | $	$ 269,935	$ 247,830
Equity distribution agreement aggregate amount | $						$ 300,000					$ 300,000	$ 300,000			$ 300,000	$ 450,000		$ 150,000
Shares issued in spinoff (in shares)														39,375,944
Issuance of common shares under 2022 Equity Incentive Plan (in shares)														64,535
IPO
Sale of Stock [Line Items]
Number of shares sold in transaction (in shares)									25,000,000
Issuance price per share (in dollars per share) | $ / shares									$ 10.50
Over-allotment option
Sale of Stock [Line Items]
Number of shares sold in transaction (in shares)									3,750,000
Public offering
Sale of Stock [Line Items]
Common stock issued (shares)				11,761,363
Issuance of common shares, net of offering costs | $				$ 242,425
Exercise price per share in dollars per share) | $ / shares				$ 22.00
Equity Distribution Agreement | Common Shares
Sale of Stock [Line Items]
Common stock issued (shares)															4,248,588
Proceeds from sale of stock | $															$ 146,250
Restricted Share Units | Legacy Plan
Sale of Stock [Line Items]
Issuance of common shares under 2022 Equity Incentive Plan (in shares)					924,093
Former Parent Stock Options | Legacy Plan
Sale of Stock [Line Items]
Issuance of common shares under 2022 Equity Incentive Plan (in shares)					2,611,392